Universitätsklinikum Schleswig-Holstein (UKSH)

Steigerung der zytotoxischen Aktivitat eines CD19 Antikorpers durch duale Fc-Optimierung (2022) Gehlert CL, Rahmati P, Boje AS, Winterberg D, Krohn S, Theocharis T, Nimmerjahn F, et al. Conference contribution VERTEBRAL FRACTURE AS RISK FACTOR FOR SUBSEQUENT VERTEBRAL FRACTURE: ICD-10 BASED ANALYSIS OF A REAL-WORLD DATABASE (2022) Glueer CC, Engelke K, Kistler M, Thomasius F, Hadji P, Schweikert B, Libanati C, Moayyeri A Conference contribution Development of brain metastases and survival outcomes upon first-line systemic therapy in BRAF mutant and BRAF wildtype melanoma patients: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG (2022) Franklin C, Mohr P, Meier F, Weichenthal M, Grimmel-Mann I, Gutzmer R, Utikal JS, et al. Conference contribution Impact of radiotherapy and sequencing of systemic therapy on survival outcomes in melanoma patients with previously untreated brain metastasis: a multicenter DeCOG study on 450 patients from the prospective skin cancer registry ADOREG (2022) Franklin C, Mohr P, Bluhm L, Grimmelmann I, Gutzmer R, Meier F, Garzarolli M, et al. Conference contribution Real-world clinical outcomes of pembrolizumab for advanced melanoma in the German ADOREG skin cancer registry (2022) Mohr P, Scherrer E, Alar V, Assaf C, Beissert S, Berking C, Eigentler T, et al. Conference contribution Predictors of long-term survival of stage IV melanoma patients: a multicenter DeCOG study on 539 patients from the prospective skin cancer registry ADOREG (2022) Placke JM, Mohr P, Bluhm L, Kahler K, Weichenthal M, Meier F, Garzarolli M, et al. Conference contribution Therapy Management of the first Recurrence after adjuvant Therapy in Stage III: multicenter real-world Data (2022) Lodde G, Forschner A, Hassel JC, Wulfken LM, Meier F, Mohr P, Kaehler K, et al. Conference contribution Effectiveness and Safety of Dabrafenib and Trametinib in Patients with BRAFV600 Mutated Metastatic Melanoma in the Real-World Setting - Final Results of the Non-Interventional COMBI-r Study (2022) Berking C, Livingstone E, Weichenthal M, Leiter-Stoeppke U, Remy J, Eigentler T, Mohr P, et al. Conference contribution Patient preferences of German and Swiss melanoma patients with regard to life-threatening side effects in the context of adjuvant immunotherapy - a qualitative GerMelaTox-A substudy (2022) Peters W, Maul LV, Huning S, Hassel JC, Heinzerling L, Loquai C, Gutzmer R, et al. Conference contribution Model soups improve performance of dermoscopic skin cancer classifiers (2022) Maron RC, Hekler A, Haggenmüller S, von Kalle C, Utikal JS, Müller V, Gaiser M, et al. Journal article